Several other analysts have also issued reports on the company. Liberum Capital raised Sanofi from a hold rating to a buy rating in a report on Friday, March 23rd. TheStreet lowered Sanofi from a b- rating to a c+ rating in a report on Tuesday, February 13th. Zacks Investment Research lowered Sanofi from a hold rating to a sell rating in a report on Wednesday, February 14th. Sanford C. Bernstein reissued a market perform rating and set a $45.00 target price (down from $50.00) on shares of Sanofi in a report on Thursday, February 8th. Finally, ValuEngine lowered Sanofi from a buy rating to a hold rating in a report on Friday, February 2nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $49.33.
SNY stock opened at $40.75 on Monday. The company has a current ratio of 1.70, a quick ratio of 1.26 and a debt-to-equity ratio of 0.25. The firm has a market cap of $101,728.05, a price-to-earnings ratio of 13.02, a PEG ratio of 2.06 and a beta of 0.85. Sanofi has a fifty-two week low of $38.14 and a fifty-two week high of $50.65.
The firm also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be paid a $1.8609 dividend. The ex-dividend date is Wednesday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.58. This represents a yield of 4.72%. Sanofi’s dividend payout ratio (DPR) is 35.14%.
Large investors have recently added to or reduced their stakes in the stock. Baldwin Brothers Inc. MA boosted its stake in Sanofi by 106.7% in the fourth quarter. Baldwin Brothers Inc. MA now owns 11,121 shares of the company’s stock valued at $478,000 after buying an additional 5,742 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Sanofi by 7.0% in the third quarter. Parametric Portfolio Associates LLC now owns 1,558,400 shares of the company’s stock valued at $77,593,000 after buying an additional 101,718 shares in the last quarter. Beacon Financial Group boosted its stake in Sanofi by 12.5% in the fourth quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock valued at $4,536,000 after buying an additional 11,761 shares in the last quarter. Epstein & White Financial LLC acquired a new stake in Sanofi in the fourth quarter valued at about $298,000. Finally, Commerzbank Aktiengesellschaft FI boosted its stake in Sanofi by 336.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 21,845 shares of the company’s stock valued at $939,000 after buying an additional 16,845 shares in the last quarter. 8.98% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Sanofi (SNY) Receives Buy Rating from Deutsche Bank” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/17/sanofi-sny-receives-buy-rating-from-deutsche-bank.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.